Introduction: In policlinic patients with disorders of lipid metabolism, systolic blood pressure (BP) is correlated to the oxLDL/LDL ratio (r = 0.3879; p < 0.0376). Therefore, we sought to determine whether BP could be lowered in metabolic syndrome (MS) patients by a phytochemical approach. In a 2-month clinical pilot study with Ginkgo biloba (EGb 761, 2 × 120 mg/d) known as excellent ROS scavenger on 11 MS patients, a novel biomarker spectrum made point-of-care theranostics feasible. Methods: ELISAs, EIAs and biosensor ellipsometry were applied. Results: The ratio oxLDL/LDL was reduced by 21.0% (p < 0.002), 8- iso -PGF 2α 39.8% (p < 0.0027), MPO 29.6% (p < 0.0137), IL-6 12.9% (p < 0.0407), hs-CRP 39.3% (p < 0.0049), Lp(a) 26.3% (p < 0.001), MMP-9 32.9% (p < 0.042), insulin 9.4% (p < 0.042), HOMA-IR 14.0% (p < 0.0244), nanoplaque formation 14.3% (p < 0.0077), nanoplaque size 23.4% (p < 0.0004), whereas SOD was augmented 17.7% (p < 0.0095), GPx 11.6% (p < 0.001), cAMP 43.5% (p < 0.001), and cGMP 32.9% (p < 0.001). Correlating ΔBP sys to ΔoxLDL/LDL resulted in a significant positive linearity allowing for 20 mmHg regulation breadth (Figure). Moreover, BP dias was reduced by 5.2 ± 2.3 mmHg (p < 0.0479) from 88.1 ± 2.1 mmHg to 82.9 ± 2.6 mmHg (p < 0.0479). The beneficial effects of ginkgo on oxidative stress parameters and on the changes in cytokine pattern could supply a mechanistic explanation. Conclusion: Ginkgo had beneficial effects on a multitude of oxidative stress, inflammatory, diabetic and arteriosclerotic biomarkers. BP dias was diminished by 5.8 ± 2.6% and reached reference values on average. Thus, ginkgo may be used as complementary drug in the treatment of borderline hypertension in MS patients.